基于新机制的抗乙肝病毒药物的研究进展.PDFVIP

现代药物与临床 Drugs Clinic 第34 卷 第5 期 2019 年5 月 ²1583 ² • 综 述 • 基于新机制的抗乙肝病毒药物的研究进展 王小磊，孙宪春，卢华军，刘小方* 烟台毓璜顶医院 肝胆胰脾外科，山东 烟台 264000 摘 要：乙型肝炎是由乙型肝炎病毒感染引起的，以肝脏炎症和坏死病变为主的一种全身性感染病。因其高致死率在世界范 围内引起广泛被关注，在我国更是一个严重的医疗卫生问题。目前为止有多种治疗乙肝的药物已应用于临床但未达到理想疗 效，同时有许多药物正处于研发阶段，并且乙型肝炎的治疗理念也在不断地更新。针对基于新机制的抗乙肝病毒药物的研究 近况进行综述，以期为临床用药提供参考。 关键词：乙型病毒性肝炎；直接抗病毒药物；宿主靶向制剂；作用机制 中图分类号：R978.7 文献标志码：A 文章编号：1674 - 5515(2019)05 - 1583 - 06 DOI: 10.7501/j.issn.1674-5515.2019.05.068 Research progress on anti-hepatitis B virus drugs based on new mechanism WANG Xiao-lei, SUN Xian-chun, LU Hua-jun, LIU Xiao-fang Department of Hepatobiliary and Pancreatic Surgery, Yantai Yuhuangding Hospital, Yantai 264000, China Abstract: Hepatitis B is a systemic infection caused by hepatitis B virus, which is mainly characterized by liver inflammation and necrosis. Because of its high mortality rate, it has caused widespread concern worldwide, and it is a serious health problem in China. So far, a lot of drugs for treating hepatitis B have been used in clinical practice, but have not achieved the desired therapeutic effect. At the same time, many drugs are in the research and development stage, and the treatment concept of hepatitis B is constantly being updated. Recent research on anti-hepatitis B virus drugs based on the new mechanism is reviewed in this article, in order to provide reference for clinical drug use. Key words: hepatitis B; direct antiviral agents; host-targeted preparation; mechanism of action 乙型病毒性肝炎（乙肝）是由乙型肝炎病毒 上常用的抗病毒药物并不能完全满足上述条件，尽 （HBV ）感染导致的一种以肝脏炎性病变为主要临 快研发强效抗乙肝病毒新型药物已成为目前国内外 床表现的慢性感染性疾病。病毒持续复制可导致肝 药物研发的重要方向。抗乙肝病毒药物大体可分为 功能异常、肝硬化甚至发展为肝癌，全球每年约有 两类：一是直接干扰病毒复制的某一环节（DAAs ）， [1] 100 万患者死于慢性乙型肝炎相关性疾病 。我国 二是通过修饰宿主细胞功能以抑制病毒复制，即宿 受其影响最为严重，国内乙肝病毒感染者约 9 000